Literature DB >> 23114748

The incidence of inherited porphyrias in Europe.

George Elder1, Pauline Harper, Michael Badminton, Sverre Sandberg, Jean-Charles Deybach.   

Abstract

Retrospective estimates of the prevalence of porphyrias have been reported but there has been no large scale prospective study of their incidence. The European Porphyria Network collected information prospectively over a 3 year period about the number of newly diagnosed symptomatic patients with an inherited porphyria (335 patients from 11 countries). Prevalence was calculated from the incidence and mean disease duration. The incidence of hepato-cellular carcinoma (HCC) in acute hepatic porphyria and the prevalence of patients with recurrent acute attacks of porphyria were also investigated. The incidence of symptomatic acute intermittent porphyria (AIP) was similar in all countries (0.13 per million per year; 95 % CI: 0.10 - 0.14) except Sweden (0.51; 95 % CI: 0.28-0.86). The incidence ratio for symptomatic AIP: variegate porphyria: hereditary coproporphyria was 1.00:0.62: 0.15. The prevalence of AIP (5.4 per million; 95 % CI: 4.5-6.3) was about half that previously reported. The prevalence of erythropoietic protoporphyria (EPP) was less uniform between countries and, in some countries, exceeded previous estimates. Fourteen new cases of HCC (11 from Sweden) were reported in patients with acute porphyria. Sixty seven patients (3 VP; 64 AIP: 53 females, 11 males) with recurrent attacks of acute porphyria were identified. The estimated percentage of patients with AIP that will develop recurrent acute attacks was 3-5 %. In conclusion, the prevalence of symptomatic acute porphyria may be decreasing, possibly due to improved management, whereas the prevalence of EPP may be increasing due to improved diagnosis and its greater recognition as a cause of photosensitivity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23114748     DOI: 10.1007/s10545-012-9544-4

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  37 in total

1.  A simple method to calculate the confidence interval of a standardized mortality ratio (SMR)

Authors:  K Ulm
Journal:  Am J Epidemiol       Date:  1990-02       Impact factor: 4.897

Review 2.  Porphyria--the UCT experience.

Authors:  P N Meissner; D M Meissner; E D Sturrock; B Davidson; R E Kirsch
Journal:  S Afr Med J       Date:  1987-12-05

3.  Variegate porphyria. Twelve years' experience in Finland.

Authors:  P Mustajoki
Journal:  Q J Med       Date:  1980

4.  The clinical and biochemical features of variegate porphyria: an analysis of 300 cases studied at Groote Schuur Hospital, Cape Town.

Authors:  L Eales; R S Day; G H Blekkenhorst
Journal:  Int J Biochem       Date:  1980

5.  Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases.

Authors:  R Kauppinen; P Mustajoki
Journal:  Medicine (Baltimore)       Date:  1992-01       Impact factor: 1.889

6.  Clinical aspects of acute intermittent porphyria in northern Sweden: a population-based study.

Authors:  Ingemar Bylesjö; Agneta Wikberg; Christer Andersson
Journal:  Scand J Clin Lab Invest       Date:  2009       Impact factor: 1.713

Review 7.  Erythropoietic protoporphyria.

Authors:  D J Todd
Journal:  Br J Dermatol       Date:  1994-12       Impact factor: 9.302

Review 8.  The molecular genetics of erythropoietic protoporphyria.

Authors:  G H Elder; L Gouya; S D Whatley; H Puy; M N Badminton; J-C Deybach
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2009-07-01       Impact factor: 1.770

9.  Molecular epidemiology of erythropoietic protoporphyria in the U.K.

Authors:  S D Whatley; N G Mason; S A Holme; A V Anstey; G H Elder; M N Badminton
Journal:  Br J Dermatol       Date:  2010-01-22       Impact factor: 9.302

Review 10.  Porphyria in Sweden.

Authors:  S Thunell; Y Floderus; A Henrichson; P Harper
Journal:  Physiol Res       Date:  2006       Impact factor: 1.881

View more
  67 in total

1.  High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria.

Authors:  Nicolas Pallet; Iadh Mami; Caroline Schmitt; Zoubida Karim; Arnaud François; Marion Rabant; Dominique Nochy; Laurent Gouya; Jean-Charles Deybach; Yichum Xu-Dubois; Eric Thervet; Hervé Puy; Alexandre Karras
Journal:  Kidney Int       Date:  2015-04-01       Impact factor: 10.612

2.  Disease pharmacokinetic-pharmacodynamic modelling in acute intermittent porphyria to support the development of mRNA-based therapies.

Authors:  Zinnia P Parra-Guillen; Antonio Fontanellas; Lei Jiang; Daniel Jericó; Paolo Martini; Diego Vera-Yunca; Marjie Hard; Lin T Guey; Iñaki F Troconiz
Journal:  Br J Pharmacol       Date:  2020-04-14       Impact factor: 8.739

3.  Experiences and concerns of patients with recurrent attacks of acute hepatic porphyria: A qualitative study.

Authors:  Hetanshi Naik; Mikayla Stoecker; Saskia C Sanderson; Manisha Balwani; Robert J Desnick
Journal:  Mol Genet Metab       Date:  2016-08-24       Impact factor: 4.797

Review 4.  Hepatic porphyria: A narrative review.

Authors:  Sumant Arora; Steven Young; Sudha Kodali; Ashwani K Singal
Journal:  Indian J Gastroenterol       Date:  2016-10-31

5.  Characterization of the hepatic transcriptome following phenobarbital induction in mice with AIP.

Authors:  Brenden Chen; Minghui Wang; Lin Gan; Bin Zhang; Robert J Desnick; Makiko Yasuda
Journal:  Mol Genet Metab       Date:  2019-01-06       Impact factor: 4.797

Review 6.  Givosiran: First Approval.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2020-02       Impact factor: 9.546

Review 7.  Porphyria Diagnostics-Part 1: A Brief Overview of the Porphyrias.

Authors:  Vaithamanithi-Mudumbai Sadagopa Ramanujam; Karl Elmo Anderson
Journal:  Curr Protoc Hum Genet       Date:  2015-07-01

8.  Acute Intermittent Porphyria: Predicted Pathogenicity of HMBS Variants Indicates Extremely Low Penetrance of the Autosomal Dominant Disease.

Authors:  Brenden Chen; Constanza Solis-Villa; Jörg Hakenberg; Wanqiong Qiao; Ramakrishnan R Srinivasan; Makiko Yasuda; Manisha Balwani; Dana Doheny; Inga Peter; Rong Chen; Robert J Desnick
Journal:  Hum Mutat       Date:  2016-09-05       Impact factor: 4.878

9.  Audit of the Use of Regular Haem Arginate Infusions in Patients with Acute Porphyria to Prevent Recurrent Symptoms.

Authors:  Joanne T Marsden; Simon Guppy; Penelope Stein; Timothy M Cox; Michael Badminton; Tricia Gardiner; Julian H Barth; M Felicity Stewart; David C Rees
Journal:  JIMD Rep       Date:  2015-03-12

Review 10.  Erythropoietic Protoporphyria and X-Linked Protoporphyria: pathophysiology, genetics, clinical manifestations, and management.

Authors:  Manisha Balwani
Journal:  Mol Genet Metab       Date:  2019-01-24       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.